Massachusetts General Hospital, Department of Radiology, Boston, MA.
Semin Roentgenol. 2022 Apr;57(2):160-167. doi: 10.1053/j.ro.2021.12.005. Epub 2021 Dec 31.
Artificial intelligence (AI) for breast imaging has rapidly moved from the experimental to implementation phase. As of this writing, Food and Drug Administration (FDA)-approved mammographic applications are available for triage, lesion detection and classification, and breast density assessment. For sonography and MRI, FDA-approved applications are available for lesion classification. Numerous other interpretive and noninterpretive AI applications are in the development phase. This article reviews AI applications for mammography, sonography, and MRI that are currently available for clinical use. In addition, clinical implementation and the future of AI for breast imaging are discussed.
人工智能（AI）在乳腺成像领域的应用已经迅速从实验阶段进入实施阶段。截至本文撰写之时，已有获得美国食品和药物管理局（FDA）批准的乳腺摄影应用程序可用于分诊、病灶检测和分类以及乳腺密度评估。对于超声和 MRI，已有获得 FDA 批准的应用程序可用于病灶分类。还有许多其他解释性和非解释性的 AI 应用程序处于开发阶段。本文回顾了目前可用于临床应用的乳腺摄影、超声和 MRI 的 AI 应用。此外，还讨论了 AI 在乳腺成像中的临床应用和未来发展。
